nach oben

Erschienen in:

01.10.2010 | Review Article

Therapeutic Approaches to Multiple Sclerosis

An Update on Failed, Interrupted, or Inconclusive Trials of Neuroprotective and Alternative Treatment Strategies

verfasst von: Sven G. Meuth, Stefan Bittner, Jochen C. Ulzheimer, Christoph Kleinschnitz, Bernd C. Kieseier, Professor Heinz Wiendl

Erschienen in: BioDrugs | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Currently approved multiple sclerosis (MS) therapeutics have a mainly anti-inflammatory mode of action. However, a number of promising clinical trials have been initiated that either focus on neuroprotection or follow completely different treatment strategies. So far, all of these clinical trials have failed to show efficacy or had to be halted prematurely because of unexpected adverse events. Some others show results that are of unknown significance with regard to a reliable assessment of true efficacy versus safety. For example, trials addressing the highly promising sodium channel blockers are under close observation because of potential adverse effects after drug withdrawal.

Previously failed therapeutic approaches in MS have indicated that there are discrepancies between the theoretical expectations and practical outcomes of different compounds. Learning from these failures helps to optimize future study designs and to reduce risks to patients. This review summarizes trials on MS treatments since 2001 that failed or were interrupted, attempts to analyze the underlying reasons for failure, and discusses the implications for our current view of MS pathogenesis, clinical practice, and the design of future studies. In order to maintain clarity, this review focuses on neuroprotective and various other treatment strategies. Clinical trials addressing anti-inflammatory research strategies are presented elsewhere.

Search strategy and selection criteria: studies were identified by a search of PubMed for publications published over the period January 2001 to March 2010, using the terms ‘multiple sclerosis’ and ‘therapy’ or ‘treatment’, and ‘trial’. Eligible studies were also identified from conference information and personal communications of the authors. Abstracts and reports from meetings were included, especially since failed trials are often not published in peer-reviewed journals. Studies were excluded if they were not published in English.

Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129: 1940–52PubMedCrossRef

Hohlfeld R, Wiendl H. The ups and downs of multiple sclerosis therapeutics. Ann Neurol 2001 Mar; 49(3): 281–4PubMedCrossRef

Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16(3): 183–200PubMedCrossRef

Kleinschnitz C, Meuth SG, Kieseier BC, et al. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007 Mar; 7(1): 35–63PubMedCrossRef

Ulzheimer JC, Meuth SG, Bittner S, et al. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. Biodrugs 2010; 24(4): 249–74PubMedCrossRef

Artemiadis AK, Anagnostouli MC. Apoptosis of oligodendrocytes and post-translational modifications of myelin basic protein in multiple sclerosis: possible role for the early stages of multiple sclerosis. Eur Neurol 2010; 63(2): 65–72PubMedCrossRef

Aarts MM, Tymianski M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr Mol Med 2004 Mar; 4(2): 137–47PubMedCrossRef

Duprat F, Lesage F, Patel AJ, et al. The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol 2000 May; 57(5): 906–12PubMed

Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000 Jan; 6(1): 67–70PubMedCrossRef

10.

Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002 Dec; 8(6): 532–3PubMedCrossRef

11.

Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 2005 Jun 15; 233(1–2): 113–5PubMedCrossRef

12.

Linker R, Gold R, Luhder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009; 29(1): 43–68PubMedCrossRef

13.

Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005 Oct; 167(1–2): 215–8PubMedCrossRef

14.

Castellano V, White LJ. Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis. J Neurol Sci 2008 Jun 15; 269(1–2): 85–91PubMedCrossRef

15.

Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Mult Scler 2007 Apr; 13(3): 313–31PubMedCrossRef

16.

Blanco Y, Saiz A, Costa M, et al. Evolution of brain-derived neurotrophic factor levels after autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurosci Lett 2005 May 20–27; 380(1–2): 122–6PubMedCrossRef

17.

Liu X, Yao DL, Webster H. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult Scler 1995 Apr; 1(1): 2–9PubMed

18.

Yao DL, Liu X, Hudson LD, et al. Insulin-like growth factor I treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 1995 Jun 20; 92(13): 6190–4PubMedCrossRef

19.

Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000 Jun; 1(3): 201–6PubMedCrossRef

20.

Frank JA, Richert N, Lewis B, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 2002 Feb; 8(1): 24–9PubMedCrossRef

21.

Harness J, Cavanagh A, Morton H, et al. A protective effect of early pregnancy factor on experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J Neurol Sci 2003 Dec 15; 216(1): 33–41PubMedCrossRef

22.

Zhang B, Harness J, Somodevilla-Torres MJ, et al. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139–151. J Neurol Sci 2000 Dec 15; 182(1): 5–15PubMedCrossRef

23.

Zhang B, Walsh MD, Nguyen KB, et al. Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed-type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. J Neurol Sci 2003 Aug 15; 212(1–2): 37–46PubMedCrossRef

24.

Athanasas-Platsis S, Zhang B, Hillyard NC, et al. Early pregnancy factor suppresses the infiltration of lymphocytes and macrophages in the spinal cord of rats during experimental autoimmune encephalomyelitis but has no effect on apoptosis. J Neurol Sci 2003 Oct 15; 214(1–2): 27–36PubMedCrossRef

25.

Johnson BJ, Le TT, Dobbin CA, et al. Heat shock protein 10 inhibits lipopolysaccharide-induced inflammatory mediator production. J Biol Chem 2005 Feb 11; 280(6): 4037–47PubMedCrossRef

26.

Broadley SA, Vanags D, Williams B, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. Mult Scler 2009 Mar; 15(3): 329–36PubMedCrossRef

27.

Craner MJ, Lo AC, Black JA, et al. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 2003 Jul; 126 (Pt 7): 1552–61PubMedCrossRef

28.

Meuth SG, Melzer N, Kleinschnitz C, et al. [Multiple sclerosis: a channelopathy? Targeting ion channels and transporters in inflammatory neurodegeneration]. Nervenarzt 2009 Apr; 80(4): 422–9PubMedCrossRef

29.

Lo AC, Saab CY, Black JA, et al. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003 Nov; 90(5): 3566–71PubMedCrossRef

30.

Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004 May; 55(5): 607–16PubMedCrossRef

31.

Bechtold DA, Miller SJ, Dawson AC, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006 Dec; 253(12): 1542–51PubMedCrossRef

32.

Waxman SG. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 2008 Mar; 4(3): 159–69PubMedCrossRef

33.

Black JA, Liu S, Carrithers M, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007 Jul; 62(1): 21–33PubMedCrossRef

34.

Kapoor R. Sodium channel blockers and neuroprotection in multiple sclerosis using lamotrigine. J Neurol Sci 2008 Nov 15; 274(1–2): 54–6PubMedCrossRef

35.

Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681–8PubMedCrossRef

36.

Kapoor R. Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design. Curr Opin Neurol 2006 Jun; 19(3): 255–9PubMedCrossRef

37.

Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006 Apr; 6(4): 528–34PubMedCrossRef

38.

Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008 Jul; 255Suppl. 3: 3–6PubMedCrossRef

39.

Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998 Feb; 50(2): 398–402PubMedCrossRef

40.

Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589–93PubMedCrossRef

41.

Haas J. High dose IVIg in the post partum period for prevention of exacerbations in MS. Multiple Sclerosis 2000; 6Suppl. 2: 18–20

42.

Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998 May; 50(5): 1273–81PubMedCrossRef

43.

Stangel M, Hartung HP. Despair of repair. J Neurol Neurosurg Psychiatry 2002 Jan; 72(1): 1–4PubMedCrossRef

44.

Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004 Sep; 251(9): 1133–7PubMedCrossRef

45.

Haas J, Maas-Enriquez M, Hartung HP. Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis: results of a retrospective multicenter observational study over five years. Mult Scler 2005 Oct; 11(5): 562–7PubMedCrossRef

46.

Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009 Sep; 15(9): 1037–42PubMedCrossRef

47.

Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev 2003; (4): CD002936

48.

Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002 Nov; 9(6): 557–63PubMedCrossRef

49.

Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion 2005 Oct; 45(10): 1640–57PubMedCrossRef

50.

Achiron A, Kishner I, Sarova-Pinhas I, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 2004 Oct; 61(10): 1515–20PubMedCrossRef

51.

Fazekas F, Lublin FD, Li D, et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008 Jul 22; 71(4): 265–71PubMedCrossRef

52.

Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Mult Scler 2005 Aug; 11(4): 433–40PubMedCrossRef

53.

Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004 Sep 25–Oct 1; 364(9440): 1149–56PubMedCrossRef

54.

Pohlau D, Przuntek H, Sailer M, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007 Nov; 13(9): 1107–17PubMedCrossRef

55.

Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004 Feb; 10(1): 89–91PubMedCrossRef

56.

Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004 Dec 14; 63(11): 2028–33PubMedCrossRef

57.

Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005 Mar 8; 64(5): 804–10PubMedCrossRef

58.

Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008 Nov; 15(11): 1163–7PubMedCrossRef

59.

Smolders J, Damoiseaux J, Menheere P, et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008 Feb; 194(1–2): 7–17PubMedCrossRef

60.

Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991 Mar; 87(3): 1103–7PubMedCrossRef

61.

Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996 Jul 23; 93(15): 7861–4PubMedCrossRef

62.

Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006 Nov 1; 177(9): 6030–7PubMed

63.

Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006 Dec 20; 296(23): 2832–8PubMedCrossRef

64.

Islam T, Gauderman WJ, Cozen W, et al. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 2007 Jul 24; 69(4): 381–8PubMedCrossRef

65.

Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol 2007 Apr; 254(4): 471–7PubMedCrossRef

66.

van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007 May; 254(5): 581–90CrossRef

67.

Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008 Nov; 14(9): 1220–4PubMedCrossRef

68.

Mahon BD, Gordon SA, Cruz J, et al. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003 Jan; 134(1–2): 128–32PubMedCrossRef

69.

Kimball SM, Ursell MR, O'Connor P, et al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007 Sep; 86(3): 645–51PubMed

70.

Achiron A, Barak Y, Miron S, et al. Alfacalcidol treatment in multiple sclerosis [letter]. Clin Neuropharmacol 2003 Mar–Apr; 26(2): 53PubMedCrossRef

71.

Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005 Sep; 76(9): 1294–6PubMedCrossRef

72.

Pozzilli C, Tomassini V, Marinelli F, et al. 'Gender gap’ in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 2003 Jan; 10(1): 95–7PubMedCrossRef

73.

Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry 2005 Feb; 76(2): 272–5PubMedCrossRef

74.

Palaszynski KM, Liu H, Loo KK, et al. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol 2004 Apr; 149(1–2): 84–9PubMedCrossRef

75.

Pike CJ, Carroll JC, Rosario ER, et al. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol 2009 Jul; 30(2): 239–58PubMedCrossRef

76.

Caruso A, Di Giorgi Gerevini V, Castiglione M, et al. Testosterone amplifies excitotoxic damage of cultured oligodendrocytes. J Neurochem 2004 Mar; 88(5): 1179–85PubMedCrossRef

77.

Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol 2007 May; 64(5): 683–8PubMedCrossRef

78.

Reske D, Haupt WF, Petereit HF. Gender change and its impact on the course of multiple sclerosis. Acta Neurol Scand 2006 May; 113(5): 347–9PubMed

79.

University of California, Los Angeles. A combination trial of Copaxone plus estriol in relapsing remitting multiple sclerosis (RRMS) (estriol in MS) [ClinicalTrials.gov identifier NCT00451204]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Jun 29]

80.

Castro HJ, Mendez-Lnocencio JI, Omidvar B, et al. A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. Allergy Asthma Proc 2005 Nov–Dec; 26(6): 470–6PubMed

81.

Wesselius T, Heersema DJ, Mostert JP, et al. A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 2005 Dec 13; 65(11): 1764–8PubMedCrossRef

82.

Lewanska M, Siger-Zajdel M, Selmaj K. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002 Nov; 9(6): 565–72PubMedCrossRef

83.

Petereit HF, Reske D, Pukrop R, et al. No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis. Mult Scler 2006 Feb; 12(1): 66–71PubMedCrossRef

84.

Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007 Aug; 13(7): 900–8PubMedCrossRef

85.

Gold SM, Chalifoux S, Giesser BS, et al. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation 2008; 5: 32PubMedCrossRef

Titel: Therapeutic Approaches to Multiple Sclerosis
An Update on Failed, Interrupted, or Inconclusive Trials of Neuroprotective and Alternative Treatment Strategies
verfasst von: Sven G. Meuth
Stefan Bittner
Jochen C. Ulzheimer
Christoph Kleinschnitz
Bernd C. Kieseier
Professor Heinz Wiendl
Publikationsdatum: 01.10.2010
Verlag: Springer International Publishing
Erschienen in: BioDrugs / Ausgabe 5/2010
Print ISSN: 1173-8804
Elektronische ISSN: 1179-190X
DOI: https://doi.org/10.2165/11537190-000000000-00000

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Therapeutic Approaches to Multiple Sclerosis

An Update on Failed, Interrupted, or Inconclusive Trials of Neuroprotective and Alternative Treatment Strategies

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Meningococcal Quadrivalent (Serogroups A, C,W135, and Y) Conjugate Vaccine (Menveo®)

Carbosilane Dendrimers to Transfect Human Astrocytes with Small Interfering RNA Targeting Human Immunodeficiency Virus

Spotlight on DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa™)†

Pazopanib

Targeted Therapies for Solid Tumors